BS_PZVHMSYN
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 13.173455978975033
- age_years
- 10.129
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.550
- HYPOXIA+0.507
- INFLAMMATORY_RESPONSE+0.413
- PANCREAS_BETA_CELLS+0.399
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.332
- MYOGENESIS+0.331
- MTORC1_SIGNALING+0.319
- ESTROGEN_RESPONSE_EARLY+0.318
- ESTROGEN_RESPONSE_LATE+0.314
- KRAS_SIGNALING_DN+0.297
Top 10 suppressed
- DNA_REPAIR-0.435
- MYC_TARGETS_V2-0.425
- OXIDATIVE_PHOSPHORYLATION-0.400
- E2F_TARGETS-0.355
- G2M_CHECKPOINT-0.293
- MYC_TARGETS_V1-0.251
- MITOTIC_SPINDLE-0.227
- WNT_BETA_CATENIN_SIGNALING-0.151
- NOTCH_SIGNALING-0.122
- ADIPOGENESIS-0.064
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1360128 | GTEX | — | 0.944 |
| 2 | SRR1355150 | GTEX | — | 0.912 |
| 3 | SRR1337648 | GTEX | — | 0.903 |
| 4 | MNG856 | — | — | 0.902 |
| 5 | SRR1472394 | GTEX | — | 0.896 |
| 6 | BS_PJPGVD62 | Ependymoma NOS | — | 0.884 |
| 7 | SRR1489177 | GTEX | — | 0.880 |
| 8 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.869 |
| 9 | SRR820256 | GTEX | — | 0.866 |
| 10 | MNG828 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| HYPOXIA | 0.507 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.413 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.399 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.332 | Inavolisib | — uncovered |
| MYOGENESIS | 0.331 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.319 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.318 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.314 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.297 | Remibrutinib | — uncovered |
| COAGULATION | 0.294 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.294 | Inavolisib | — uncovered |
| COMPLEMENT | 0.292 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.278 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.268 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.259 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.252 | Inavolisib | — uncovered |
| APOPTOSIS | 0.243 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.216 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.215 | Idelalisib | — uncovered |